Back to Journals » Clinical Ophthalmology » Volume 4

Cytotoxicity of prostaglandin analog eye drops preserved with benzalkonium chloride in multiple corneoconjunctival cell lines

Authors Ayaki M, Iwasawa A

Published 17 August 2010 Volume 2010:4 Pages 919—924


Review by Single anonymous peer review

Peer reviewer comments 2

Masahiko Ayaki1, Atsuo Iwasawa2

1Department of Ophthalmology, Saitama National Hospital, Wako, 2Department of Clinical Pathology, Showa University Fujigaoka Hospital, Yokohama, Japan

Purpose: This study evaluated the cytotoxicity of five prostaglandin analog ophthalmic ­solutions on four ocular surface cell lines, ie, Chang (human conjunctiva), SIRC (rabbit cornea), RC-1 (rabbit cornea), and BCE C/D-1b (bovine cornea).

Methods: Cell viability was measured by neutral red and MTT assays in cells treated for 10, 30, or 60 minutes with various doses of prostaglandins (undiluted, and 2- and 10-fold dilutions). The number of cell lines with viability ≥50% in the presence of selected dilution of the drug (CVS50) was used for comparison. In addition, 24 cell viability comparisons (four cell lines, two assays, and three exposure times) were made between latanoprost (Xalatan®) and each other solution at each dose. A comparison between the newly introduced tafluprost (Tapros®) with 0.01% benzalkonium chloride was also made.

Results: The order of cell viability determined by CVS50 was Travatan Z® (travoprost with the SofZia system)> Tapros ≥ Travatan® (travoprost) = Xalatan > Rescula® (unoproston). This was consistent with the results of direct comparisons between Xalatan and the other drugs. There was no clear difference in cell viability between Tapros and benzalkonium chloride.

Conclusions: Use of two assays, multiple cell lines, and various dilutions and exposure times provided a unique evaluation of cytotoxicity among ophthalmic solutions. CVS50 was useful for comparison of the cell viability of the solutions.

Keywords: glaucoma, cornea, cell viability score

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.